ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar

View Author Information
Department of Pharmaceutical/Medicinal Chemistry II, Institute of Pharmacy, and Institute of Organic Chemistry, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstrasse 31, D-93053 Regensburg, Germany, Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Im Neuenheimer Feld 366, D-69120 Heidelberg, Germany
* To whom correspondence should be addressed. Phone: +49-941 9434827. Fax: +49-941 9434820. E-mail: [email protected]
†Department of Pharmaceutical/Medicinal Chemistry II, Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg.
‡Institute of Organic Chemistry, Faculty of Chemistry and Pharmacy, University of Regensburg.
§Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg.
Cite this: J. Med. Chem. 2009, 52, 4, 1190–1197
Publication Date (Web):January 26, 2009
Copyright © 2009 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    The efflux pumps ABCB1 (p-gp, MDR1) and ABCG2 (BCRP) are expressed to a high extent by endothelial cells at the blood−brain barrier (BBB) and other barrier tissues and are involved in drug resistance of tumor (stem) cells. Whereas numerous ABCB1 inhibitors are known, only a few ABCG2 modulators with submicromolar activity have been published. Starting from tariquidar (4) analogues as ABCB1 modulators, minimal structural modifications resulted in a drastic shift in favor of ABCG2 inhibition. Highest potency was found when the 3,4-dimethoxy-2-(quinoline-3-carbonylamino)benzoyl moiety in 4 was replaced with a 4-methoxycarbonylbenzoyl moiety bearing a hetarylcarboxamido group in 3-position, e.g., quinoline-3-carboxamido (5, IC50: 119 nM) or quinoline-2-carboxamido (6, IC50: 60 nM, flow cytometric mitoxantrone efflux assay, topotecan-resistant MCF-7 breast cancer cells); the selectivity for ABCG2 over ABCB1 was about 100−500 fold and the compounds were inactive at ABCC2 (MRP2). Chemosensitivity assays against MCF-7/Topo cells revealed that the nontoxic inhibitor 6 completely reverted ABCG2-mediated topotecan resistance at concentrations >100 nM, whereas 5 showed ABCG2 independent cytotoxicity. ABCG2 inhibitors might be useful for cancer treatment with respect to reversal of multidrug resistance, overcoming the BBB and targeting of tumor stem cells.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    Jump To

    Experimental details and analytical data for the intermediates 16d, 18ae, 19ae and for the target compounds 5, 715, 1H- and 13C NMR spectra and HPLC analysis including tracings of key target compounds. This material is available free of charge via the Internet at

    Terms & Conditions

    Electronic Supporting Information files are available without a subscription to ACS Web Editions. The American Chemical Society holds a copyright ownership interest in any copyrightable Supporting Information. Files available from the ACS website may be downloaded for personal use only. Users are not otherwise permitted to reproduce, republish, redistribute, or sell any Supporting Information from the ACS website, either in whole or in part, in either machine-readable form or any other form without permission from the American Chemical Society. For permission to reproduce, republish and redistribute this material, requesters must process their own requests via the RightsLink permission system. Information about how to use the RightsLink permission system can be found at

    Cited By

    This article is cited by 121 publications.

    1. Qianwen Guan, Shuaishuai Xing, Lei Wang, Jiawei Zhu, Can Guo, Chunlei Xu, Qun Zhao, Yulan Wu, Yao Chen, Haopeng Sun. Triazoles in Medicinal Chemistry: Physicochemical Properties, Bioisosterism, and Application. Journal of Medicinal Chemistry 2024, Article ASAP.
    2. Hui Li, Sheng-Lie Zhang, Yan-Han Jia, Qian Li, Zi-Wen Feng, Shi-Duo Zhang, Wei Zheng, Ye-Ling Zhou, Lin-Lin Li, Xue-Chun Liu, Ya-Qiong Chen, Hui Peng, Qi-Dong You, Xiao-Li Xu. Imidazo[1,2-a]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance. Journal of Medicinal Chemistry 2023, 66 (4) , 2804-2831.
    3. Sachin Puri, Katja Stefan, Sharuk L. Khan, Jens Pahnke, Sven Marcel Stefan, Kapil Juvale. Indole Derivatives as New Structural Class of Potent and Antiproliferative Inhibitors of Monocarboxylate Transporter 1 (MCT1; SLC16A1). Journal of Medicinal Chemistry 2023, 66 (1) , 657-676.
    4. Katja Silbermann, Jiyang Li, Vigneshwaran Namasivayam, Fabian Baltes, Gerd Bendas, Sven Marcel Stefan, Michael Wiese. Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists. Journal of Medicinal Chemistry 2020, 63 (18) , 10412-10432.
    5. Diana Peña-Solórzano, Matthias Scholler, Günther Bernhardt, Armin Buschauer, Burkhard König, Cristian Ochoa-Puentes. Tariquidar-Related Chalcones and Ketones as ABCG2 Modulators. ACS Medicinal Chemistry Letters 2018, 9 (8) , 854-859.
    6. Michael K. Krapf, Jennifer Gallus, Sahel Vahdati, Michael Wiese. New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold. Journal of Medicinal Chemistry 2018, 61 (8) , 3389-3408.
    7. Katja Stefan, Sven Marcel Schmitt, and Michael Wiese . 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein. Journal of Medicinal Chemistry 2017, 60 (21) , 8758-8780.
    8. Andreas Schäfer, Sebastian C. Köhler, Markus Lohe, Michael Wiese, and Martin Hiersemann . Synthesis of Homoverrucosanoid-Derived Esters and Evaluation as MDR Modulators. The Journal of Organic Chemistry 2017, 82 (19) , 10504-10522.
    9. Thomas Wanek, Kerstin Römermann, Severin Mairinger, Johann Stanek, Michael Sauberer, Thomas Filip, Alexander Traxl, Claudia Kuntner, Jens Pahnke, Florian Bauer, Thomas Erker, Wolfgang Löscher, Markus Müller, and Oliver Langer . Factors Governing P-Glycoprotein-Mediated Drug–Drug Interactions at the Blood–Brain Barrier Measured with Positron Emission Tomography. Molecular Pharmaceutics 2015, 12 (9) , 3214-3225.
    10. Iris L. K. Wong, Bao-Chao Wang, Jian Yuan, Liang-Xing Duan, Zhen Liu, Tao Liu, Xue-Min Li, Xuesen Hu, Xiao-Yu Zhang, Tao Jiang, Sheng-Biao Wan, and Larry M. C. Chow . Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives. Journal of Medicinal Chemistry 2015, 58 (11) , 4529-4549.
    11. Sebastian C. Köhler and Michael Wiese . HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2). Journal of Medicinal Chemistry 2015, 58 (9) , 3910-3921.
    12. Gustavo Jabor Gozzi, Zouhair Bouaziz, Evelyn Winter, Nathalia Daflon-Yunes, Dagmar Aichele, Abdelhamid Nacereddine, Christelle Marminon, Glaucio Valdameri, Waël Zeinyeh, Andre Bollacke, Jean Guillon, Aline Lacoudre, Noël Pinaud, Silvia M. Cadena, Joachim Jose, Marc Le Borgne, and Attilio Di Pietro . Converting Potent Indeno[1,2-b]indole Inhibitors of Protein Kinase CK2 into Selective Inhibitors of the Breast Cancer Resistance Protein ABCG2. Journal of Medicinal Chemistry 2015, 58 (1) , 265-277.
    13. Piero Tardia, Angela Stefanachi, Mauro Niso, Diana Antonella Stolfa, Giuseppe Felice Mangiatordi, Domenico Alberga, Orazio Nicolotti, Gianluca Lattanzi, Angelo Carotti, Francesco Leonetti, Roberto Perrone, Francesco Berardi, Amalia Azzariti, Nicola Antonio Colabufo, and Saverio Cellamare . Trimethoxybenzanilide-Based P-Glycoprotein Modulators: An Interesting Case of Lipophilicity Tuning by Intramolecular Hydrogen Bonding. Journal of Medicinal Chemistry 2014, 57 (15) , 6403-6418.
    14. Gergely Szakács, Matthew D. Hall, Michael M. Gottesman, Ahcène Boumendjel, Remy Kachadourian, Brian J. Day, Hélène Baubichon-Cortay, and Attilio Di Pietro . Targeting the Achilles Heel of Multidrug-Resistant Cancer by Exploiting the Fitness Cost of Resistance. Chemical Reviews 2014, 114 (11) , 5753-5774.
    15. Evelyn Winter, Florine Lecerf-Schmidt, Gustavo Gozzi, Basile Peres, Mark Lightbody, Charlotte Gauthier, Csilla Ozvegy-Laczka, Gergely Szakacs, Balazs Sarkadi, Tânia B. Creczynski-Pasa, Ahcène Boumendjel, and Attilio Di Pietro . Structure–Activity Relationships of Chromone Derivatives toward the Mechanism of Interaction with and Inhibition of Breast Cancer Resistance Protein ABCG2. Journal of Medicinal Chemistry 2013, 56 (24) , 9849-9860.
    16. Cristian Ochoa-Puentes, Stefanie Bauer, Matthias Kühnle, Günther Bernhardt, Armin Buschauer, and Burkhard König . Benzanilide–Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type ABCG2 Modulators. ACS Medicinal Chemistry Letters 2013, 4 (4) , 393-396.
    17. Ishrat Jabeen, Karin Pleban, Uwe Rinner, Peter Chiba, and Gerhard F. Ecker . Structure–Activity Relationships, Ligand Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug Transporter P-Glycoprotein. Journal of Medicinal Chemistry 2012, 55 (7) , 3261-3273.
    18. Glaucio Valdameri, Luciana Pereira Rangel, Carmela Spatafora, Jérôme Guitton, Charlotte Gauthier, Ophélie Arnaud, Antonio Ferreira-Pereira, Pierre Falson, Sheila M. B. Winnischofer, Maria E. M. Rocha, Corrado Tringali, and Attilio Di Pietro . Methoxy Stilbenes as Potent, Specific, Untransported, and Noncytotoxic Inhibitors of Breast Cancer Resistance Protein. ACS Chemical Biology 2012, 7 (2) , 322-330.
    19. Glaucio Valdameri, Estelle Genoux-Bastide, Basile Peres, Charlotte Gauthier, Jérôme Guitton, Raphaël Terreux, Sheila M. B. Winnischofer, Maria E. M. Rocha, Ahcène Boumendjel, and Attilio Di Pietro . Substituted Chromones as Highly Potent Nontoxic Inhibitors, Specific for the Breast Cancer Resistance Protein. Journal of Medicinal Chemistry 2012, 55 (2) , 966-970.
    20. Pavitra Kannan, Sanjay Telu, Suneet Shukla, Suresh V. Ambudkar, Victor W. Pike, Christer Halldin, Michael M. Gottesman, Robert B. Innis, and Matthew D. Hall . The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2). ACS Chemical Neuroscience 2011, 2 (2) , 82-89.
    21. Hans-Georg Häcker, Stefan Leyers, Jeanette Wiendlocha, Michael Gütschow and Michael Wiese . Aromatic 2-(Thio)ureidocarboxylic Acids As a New Family of Modulators of Multidrug Resistance-Associated Protein 1: Synthesis, Biological Evaluation, and Structure−Activity Relationships. Journal of Medicinal Chemistry 2009, 52 (15) , 4586-4595.
    22. Daniela Damiani, Mario Tiribelli. ATP-Binding Cassette Subfamily G Member 2 in Acute Myeloid Leukemia: A New Molecular Target?. Biomedicines 2024, 12 (1) , 111.
    23. Yasmeen Cheema, Kenneth J. Linton, Ishrat Jabeen. Molecular Modeling Studies to Probe the Binding Hypothesis of Novel Lead Compounds against Multidrug Resistance Protein ABCB1. Biomolecules 2024, 14 (1) , 114.
    24. Philipp Stockmann, Lydia Kuhnert, Tamara Krajnović, Sanja Mijatović, Danijela Maksimović‐Ivanić, Walther Honscha, Evamarie Hey‐Hawkins. Carboranes as Potent Phenyl Mimetics: A Comparative Study on the Reversal of ABCG2‐Mediated Drug Resistance by Carboranylquinazolines and Their Organic Isosteres. ChemMedChem 2023, 3
    25. Chung-Pu Wu, Sung-Han Hsiao, Yu-Shan Wu. Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2. Drug Resistance Updates 2023, 71 , 101011.
    26. Junjie Zhu, Saifei Lei, Jie Lu, Yixuan Hao, Qi Qian, Aaron S. Devanathan, Zhiwei Feng, Xiang-Qun Xie, Peter Wipf, Xiaochao Ma. Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors. European Journal of Medicinal Chemistry 2023, 259 , 115666.
    27. Laura Braconi, Silvia Dei, Marialessandra Contino, Chiara Riganti, Gianluca Bartolucci, Dina Manetti, Maria Novella Romanelli, Maria Grazia Perrone, Nicola Antonio Colabufo, Stefano Guglielmo, Elisabetta Teodori. Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and elacridar: New potent P-gp modulators acting as MDR reversers. European Journal of Medicinal Chemistry 2023, 259 , 115716.
    28. Pavle Stojković, Ana Kostić, Ema Lupšić, Nataša Terzić Jovanović, Miroslav Novaković, Paraskev Nedialkov, Antoaneta Trendafilova, Milica Pešić, Igor M. Opsenica. Novel hybrids of sclareol and 1,2,4-triazolo[1,5-a]pyrimidine show collateral sensitivity in multidrug-resistant glioblastoma cells. Bioorganic Chemistry 2023, 138 , 106605.
    29. Rishabha Malviya, Arun Kumar Singh, Deepika Yadav. Epithelial to Mesenchymal Transition (EMT). 2023, 131-153.
    30. Stefanie A. Baril, Tomoka Gose, John D. Schuetz. How Cryo-EM Has Expanded Our Understanding of Membrane Transporters. Drug Metabolism and Disposition 2023, 51 (8) , 904-922.
    31. Prithwish Kola, Prasanth Kumar Bhusetty Nagesh, Pritam Kumar Roy, K. Deepak, Rui Luis Reis, Subhas C. Kundu, Mahitosh Mandal. Innovative nanotheranostics: Smart nanoparticles based approach to overcome breast cancer stem cells mediated chemo‐ and radioresistances. WIREs Nanomedicine and Nanobiotechnology 2023, 15 (4)
    32. Daniela Damiani, Mario Tiribelli. ABCG2 in Acute Myeloid Leukemia: Old and New Perspectives. International Journal of Molecular Sciences 2023, 24 (8) , 7147.
    33. Yasmeen Cheema, Yusra Sajid Kiani, Kenneth J. Linton, Ishrat Jabeen. Identification and Empiric Evaluation of New Inhibitors of the Multidrug Transporter P-Glycoprotein (ABCB1). International Journal of Molecular Sciences 2023, 24 (6) , 5298.
    34. Ali Rasouli, Qin Yu, Sepehr Dehghani-Ghahnaviyeh, Po-Chao Wen, Julia Kowal, Kaspar P. Locher, Emad Tajkhorshid. Differential dynamics and direct interaction of bound ligands with lipids in multidrug transporter ABCG2. Proceedings of the National Academy of Sciences 2023, 120 (1)
    35. Noor Khalid Saleh, Al-Khafaji Mayada Nazar, Raghad Ibrahim. Overcome treatment-resistance in breast cancer cells: Review. 2023, 020017.
    36. Elisabetta Teodori, Laura Braconi, Dina Manetti, Maria Novella Romanelli, Silvia Dei. The Tetrahydroisoquinoline Scaffold in ABC Transporter Inhibitors that Act as Multidrug Resistance (MDR) Reversers. Current Topics in Medicinal Chemistry 2022, 22 (31) , 2535-2569.
    37. Md Moinul, Sk Abdul Amin, Tarun Jha, Shovanlal Gayen. Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development. European Journal of Medicinal Chemistry 2022, 241 , 114628.
    38. Sirajudheen Anwar, Jonaid Ahmad Malik, Sakeel Ahmed, Verma Abhishek Kameshwar, Jowaher Alanazi, Abdulwahab Alamri, Nafees Ahemad. Can Natural Products Targeting EMT Serve as the Future Anticancer Therapeutics?. Molecules 2022, 27 (22) , 7668.
    39. Ingrid Fatima Zattoni, Letícia Carani Delabio, Julia de Paula Dutra, Diogo Henrique Kita, Gustavo Scheiffer, Marina Hembecker, Giovana da Silva Pereira, Vivian Rotuno Moure, Glaucio Valdameri. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. European Journal of Medicinal Chemistry 2022, 237 , 114346.
    40. Irene Hernández-Lozano, Severin Mairinger, Thomas Filip, Michael Sauberer, Thomas Wanek, Johann Stanek, Johannes A. Sake, Thomas Pekar, Carsten Ehrhardt, Oliver Langer. PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats. Journal of Controlled Release 2022, 342 , 44-52.
    41. Ali Daowd, Samina Abidi, Syed Sibte Raza Abidi. A Knowledge Graph Completion Method Applied to Literature-Based Discovery for Predicting Missing Links Targeting Cancer Drug Repurposing. 2022, 24-34.
    42. Ingrid Fatima Zattoni, Thales Kronenberger, Diogo Henrique Kita, Lais Danciguer Guanaes, Matheus Murmel Guimarães, Larissa de Oliveira Prado, Melanie Ziasch, Luis C. Vesga, Fabiane Gomes de Moraes Rego, Geraldo Picheth, Marcos Brown Gonçalves, Miguel D. Noseda, Diogo R.B. Ducatti, Antti Poso, Robert W. Robey, Suresh V. Ambudkar, Vivian Rotuno Moure, Alan Guilherme Gonçalves, Glaucio Valdameri. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2). Chemico-Biological Interactions 2022, 351 , 109718.
    43. Julia Kowal, Dongchun Ni, Scott M. Jackson, Ioannis Manolaridis, Henning Stahlberg, Kaspar P. Locher. Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2. Journal of Molecular Biology 2021, 433 (13) , 166980.
    44. Minh-Tri Le, Viet-Nham Hoang, Dac-Nhan Nguyen, Thi-Hoang-Linh Bui, Thien-Vy Phan, Phuong Nguyen-Hoai Huynh, Thanh-Dao Tran, Khac-Minh Thai. Structure-Based Discovery of ABCG2 Inhibitors: A Homology Protein-Based Pharmacophore Modeling and Molecular Docking Approach. Molecules 2021, 26 (11) , 3115.
    45. Mahmoud Zaki El-Readi, Ahmed M. Al-Abd, Mohammad A. Althubiti, Riyad A. Almaimani, Hiba Saeed Al-Amoodi, Mohamed Lotfy Ashour, Michael Wink, Safaa Yehia Eid. Multiple Molecular Mechanisms to Overcome Multidrug Resistance in Cancer by Natural Secondary Metabolites. Frontiers in Pharmacology 2021, 12
    46. Frauke Antoni, David Wifling, Günther Bernhardt. Water-soluble inhibitors of ABCG2 (BCRP) – A fragment-based and computational approach. European Journal of Medicinal Chemistry 2021, 210 , 112958.
    47. Lingna Wu, Jianming Liu, Jinxia Hou, Tao Zhan, Li Yuan, Fanglan Liu, Yuqing Xiong, Jinfang Hu, Chunhua Xia. Interactions of the major effective components in Shengmai formula with breast cancer resistance protein at the cellular and vesicular levels. Biomedicine & Pharmacotherapy 2021, 133 , 110939.
    48. M. Asif, M. Usman, Shahid Ayub, Sahar Farhat, Zilli Huma, Jawad Ahmed, Mohammad A. Kamal, Deema Hussein, Aneela Javed, Ishaq Khan. Role of ATP-Binding Cassette Transporter Proteins in CNS Tumors: Resistance- Based Perspectives and Clinical Updates. Current Pharmaceutical Design 2020, 26 (37) , 4747-4763.
    49. Pavitra Kannan, András Füredi, Sabina Dizdarevic, Thomas Wanek, Severin Mairinger, Jeffrey Collins, Theresa Falls, R. Michael van Dam, Divya Maheshwari, Jason T. Lee, Gergely Szakács, Oliver Langer. In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance. European Journal of Nuclear Medicine and Molecular Imaging 2020, 47 (8) , 2026-2035.
    50. Frauke Antoni, Manuel Bause, Matthias Scholler, Stefanie Bauer, Simone A. Stark, Scott M. Jackson, Ioannis Manolaridis, Kaspar P. Locher, Burkhard König, Armin Buschauer, Günther Bernhardt. Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP). European Journal of Medicinal Chemistry 2020, 191 , 112133.
    51. Elisabetta Teodori, Marialessandra Contino, Chiara Riganti, Gianluca Bartolucci, Laura Braconi, Dina Manetti, Maria Novella Romanelli, Alfonso Trezza, Asimidis Athanasios, Ottavia Spiga, Maria Grazia Perrone, Roberta Giampietro, Elena Gazzano, Milena Salerno, Nicola Antonio Colabufo, Silvia Dei. Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers. European Journal of Medicinal Chemistry 2019, 182 , 111655.
    52. Katja Silbermann, Chetan P. Shah, Niteshkumar U. Sahu, Kapil Juvale, Sven Marcel Stefan, Prashant S. Kharkar, Michael Wiese. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2. European Journal of Medicinal Chemistry 2019, 164 , 193-213.
    53. Sven Marcel Stefan, Michael Wiese. Small‐molecule inhibitors of multidrug resistance‐associated protein 1 and related processes: A historic approach and recent advances. Medicinal Research Reviews 2019, 39 (1) , 176-264.
    54. Chao Guo, Fangyuan Liu, Jie Qi, Jiahui Ma, Shiqi Lin, Caiyun Zhang, Qian Zhang, Hangyu Zhang, Rong Lu, Xia Li. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells. Molecules 2018, 23 (12) , 3264.
    55. Andreas Noack, Birthe Gericke, Maren von Köckritz-Blickwede, Arne Menze, Sandra Noack, Ingo Gerhauser, Felix Osten, Hassan Y. Naim, Wolfgang Löscher. Mechanism of drug extrusion by brain endothelial cells via lysosomal drug trapping and disposal by neutrophils. Proceedings of the National Academy of Sciences 2018, 115 (41)
    56. Scott M. Jackson, Ioannis Manolaridis, Julia Kowal, Melanie Zechner, Nicholas M. I. Taylor, Manuel Bause, Stefanie Bauer, Ruben Bartholomaeus, Guenther Bernhardt, Burkhard Koenig, Armin Buschauer, Henning Stahlberg, Karl-Heinz Altmann, Kaspar P. Locher. Structural basis of small-molecule inhibition of human multidrug transporter ABCG2. Nature Structural & Molecular Biology 2018, 25 (4) , 333-340.
    57. . Tetrahydroisoquinolines. 2018, 356-413.
    58. Nehaben A. Gujarati, Leli Zeng, Pranav Gupta, Zhe-Sheng Chen, Vijaya L. Korlipara. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors. Bioorganic & Medicinal Chemistry Letters 2017, 27 (20) , 4698-4704.
    59. Diana Peña‐Solórzano, Simone Alexandra Stark, Burkhard König, Cesar Augusto Sierra, Cristian Ochoa‐Puentes. ABCG2/BCRP: Specific and Nonspecific Modulators. Medicinal Research Reviews 2017, 37 (5) , 987-1050.
    60. Elisabetta Teodori, Silvia Dei, Gianluca Bartolucci, Maria Grazia Perrone, Dina Manetti, Maria Novella Romanelli, Marialessandra Contino, Nicola Antonio Colabufo. Structure–Activity Relationship Studies on 6,7‐Dimethoxy‐2‐phenethyl‐1,2,3,4‐tetrahydroisoquinoline Derivatives as Multidrug Resistance Reversers. ChemMedChem 2017, 12 (16) , 1369-1379.
    61. Noor Hussein, Haneen Amawi, Chandrabose Karthikeyan, F. Scott Hall, Roopali Mittal, Piyush Trivedi, Charles R. Ashby, Amit K. Tiwari. The dopamine D 3 receptor antagonists PG01037, NGB2904, SB277011A, and U99194 reverse ABCG2 transporter-mediated drug resistance in cancer cell lines. Cancer Letters 2017, 396 , 167-180.
    62. Oliver Langer. PET Imaging of ABC Transporters at the Blood–Brain Barrier. 2017, 179-198.
    63. Julienne K. Muenzner, Bernhard Biersack, Alexander Albrecht, Tobias Rehm, Ulrike Lacher, Wolfgang Milius, Angela Casini, Jing‐Jing Zhang, Ingo Ott, Viktor Brabec, Olga Stuchlikova, Ion C. Andronache, Leonard Kaps, Detlef Schuppan, Rainer Schobert. Ferrocenyl‐Coupled N‐Heterocyclic Carbene Complexes of Gold(I): A Successful Approach to Multinuclear Anticancer Drugs. Chemistry – A European Journal 2016, 22 (52) , 18953-18962.
    64. Florian Schmitt, Heidrun Draut, Bernhard Biersack, Rainer Schobert. Halogenated naphthochalcones and structurally related naphthopyrazolines with antitumor activity. Bioorganic & Medicinal Chemistry Letters 2016, 26 (21) , 5168-5171.
    65. Bowen Du, Joong Shim. Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules 2016, 21 (7) , 965.
    66. Theresa Schwarz, Floriane Montanari, Anna Cseke, Katrin Wlcek, Lene Visvader, Sarah Palme, Peter Chiba, Karl Kuchler, Ernst Urban, Gerhard F. Ecker. Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P‐Glycoprotein (P‐gp) and Breast Cancer Resistance Protein (BCRP). ChemMedChem 2016, 11 (12) , 1380-1394.
    67. José Esteban Obreque-Balboa, Qiu Sun, Günther Bernhardt, Burkhard König, Armin Buschauer. Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization. European Journal of Medicinal Chemistry 2016, 109 , 124-133.
    68. Tobias Rehm, Matthias Rothemund, Julienne K. Muenzner, Awal Noor, Rhett Kempe, Rainer Schobert. Novel cis-[(NHC) 1 (NHC) 2 (L)Cl]platinum( ii ) complexes – synthesis, structures, and anticancer activities. Dalton Transactions 2016, 45 (39) , 15390-15398.
    69. Elizabeth Fox, Brigitte C. Widemann, Devang Pastakia, Clara C. Chen, Sherry X. Yang, Diane Cole, Frank M. Balis. Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemotherapy and Pharmacology 2015, 76 (6) , 1273-1283.
    70. Lora D. Weidner, Sami S. Zoghbi, Shuiyu Lu, Suneet Shukla, Suresh V. Ambudkar, Victor W. Pike, Jan Mulder, Michael M. Gottesman, Robert B. Innis, Matthew D. Hall. The Inhibitor Ko143 Is Not Specific for ABCG2. Journal of Pharmacology and Experimental Therapeutics 2015, 354 (3) , 384-393.
    71. Stefan Huber, Anja K. Wege, Günther Bernhardt, Armin Buschauer, Gero Brockhoff. Topotecan‐induced ABCG2 expression in MCF‐7 cells is associated with decreased CD24 and EpCAM expression and a loss of tumorigenicity. Cytometry Part A 2015, 87 (8) , 707-716.
    72. Xu-Qin Li, Lin Wang, Yan Lei, Tao Hu, Fei-Long Zhang, Chi-Hin Cho, Kenneth K.W. To. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives. European Journal of Medicinal Chemistry 2015, 101 , 560-572.
    73. Kerstin Römermann, Renate Helmer, Wolfgang Löscher. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2). Neuropharmacology 2015, 93 , 7-14.
    74. Daigo Hayashi, Naoki Tsukioka, Yutaka Inoue, Yoshiki Matsubayashi, Toshimasa Iizuka, Kazuhiro Higuchi, Yoji Ikegami, Tomomi Kawasaki. Synthesis and ABCG2 inhibitory evaluation of 5-N-acetylardeemin derivatives. Bioorganic & Medicinal Chemistry 2015, 23 (9) , 2010-2023.
    75. Cynthia X. Ma, Tomás Reinert, Izabela Chmielewska, Matthew J. Ellis. Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer 2015, 15 (5) , 261-275.
    76. K. Römermann, J. P. Bankstahl, W. Löscher, M. Bankstahl. Pilocarpine-Induced Convulsive Activity Is Limited by Multidrug Transporters at the Rodent Blood-Brain Barrier. Journal of Pharmacology and Experimental Therapeutics 2015, 353 (2) , 351-359.
    77. Pratima Nangia-Makker, Yingjie Yu, Lulu Farhana, Kulsoom Ahmed, Adhip P. N. Majumdar. Colorectal Cancer Stem Cells. 2015, 227-245.
    78. Qingcheng Mao, Jashvant D. Unadkat. Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update. The AAPS Journal 2015, 17 (1) , 65-82.
    79. Sangeetha Krishnamurthy, Xiyu Ke, Yi Yan Yang. Delivery of Therapeutics Using Nanocarriers for Targeting Cancer Cells and Cancer Stem Cells. Nanomedicine 2015, 10 (1) , 143-160.
    80. Manuel Tonigold, Annette Rossmann, Marie Meinold, Michael Bette, Melanie Märken, Katharina Henkenius, Anne C. Bretz, Gavin Giel, Chengzhong Cai, Fiona R. Rodepeter, Vladimir Beneš, Reidar Grénman, Thomas E. Carey, Hermann Lage, Thorsten Stiewe, Andreas Neubauer, Jochen A. Werner, Cornelia Brendel, Robert Mandic. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53mut exhibits ATP-binding cassette transporter upregulation and high glutathione levels. Journal of Cancer Research and Clinical Oncology 2014, 140 (10) , 1689-1704.
    81. Floriane Montanari, Gerhard F. Ecker. BCRP Inhibition: from Data Collection to Ligand‐Based Modeling. Molecular Informatics 2014, 33 (5) , 322-331.
    82. Marcel Benadiba, Heli Savolainen, Nicola A. Colabufo, Albert D. Windhorst, Aren van Waarde, Gert Luurtsema. PET Imaging of ABC Transporters in the BBB. 2014, 625-652.
    83. Zhangli Dong, Dongmei Lai. Isolation of Cancer Stem Cells Showing Drug Resistance in the Human Epithelia Ovarian Cancer. 2014, 103-109.
    84. Stefanie Bauer, Cristian Ochoa‐Puentes, Qiu Sun, Manuel Bause, Günther Bernhardt, Burkhard König, Armin Buschauer. Quinoline Carboxamide‐Type ABCG2 Modulators: Indole and Quinoline Moieties as Anilide Replacements. ChemMedChem 2013, 8 (11) , 1773-1778.
    85. Arun K. Iyer, Amit Singh, Srinivas Ganta, Mansoor M. Amiji. Role of integrated cancer nanomedicine in overcoming drug resistance. Advanced Drug Delivery Reviews 2013, 65 (13-14) , 1784-1802.
    86. Ilza K. Pajeva, Katja Sterz, Matthias Christlieb, Kerstin Steggemann, Federico Marighetti, Michael Wiese. Interactions of the Multidrug Resistance Modulators Tariquidar and Elacridar and their Analogues with P‐glycoprotein. ChemMedChem 2013, 8 (10) , 1701-1713.
    87. Florine Lecerf-Schmidt, Basile Peres, Glaucio Valdameri, Charlotte Gauthier, Evelyn Winter, Léa Payen, Attilio Di Pietro, Ahcène Boumendjel. ABCG2: Recent Discovery of Potent and Highly Selective Inhibitors. Future Medicinal Chemistry 2013, 5 (9) , 1037-1045.
    88. Jens P. Bankstahl, Marion Bankstahl, Kerstin Römermann, Thomas Wanek, Johann Stanek, Albert D. Windhorst, Maren Fedrowitz, Thomas Erker, Markus Müller, Wolfgang Löscher, Oliver Langer, Claudia Kuntner. Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study. Drug Metabolism and Disposition 2013, 41 (4) , 754-762.
    89. Thomas Wanek, Severin Mairinger, Oliver Langer. Radioligands targeting P‐glycoprotein and other drug efflux proteins at the blood–brain barrier. Journal of Labelled Compounds and Radiopharmaceuticals 2013, 56 (3-4) , 68-77.
    90. Yue-Li Sun, Jun-Jiang Chen, Priyank Kumar, Kang Chen, Kamlesh Sodani, Atish Patel, Yang-Lu Chen, Si-Dong Chen, Wen-Qi Jiang, Zhe-Sheng Chen, . Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar. PLoS ONE 2013, 8 (2) , e55576.
    91. S. Murray, E. Briasoulis, H. Linardou, D. Bafaloukos, C. Papadimitriou. Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treatment Reviews 2012, 38 (7) , 890-903.
    92. Jian Yuan, Iris L.K. Wong, Tao Jiang, Si Wen Wang, Tao Liu, Bin Jin Wen, Larry M.C. Chow, Biao Wan Sheng. Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells. European Journal of Medicinal Chemistry 2012, 54 , 413-422.
    93. Glaucio Valdameri, Estelle Genoux‐Bastide, Charlotte Gauthier, Basile Peres, Raphaël Terreux, Sheila M. B. Winnischofer, Maria E. M. Rocha, Attilio Di Pietro, Ahcène Boumendjel. 6‐Halogenochromones Bearing Tryptamine: One‐Step Access to Potent and Highly Selective Inhibitors of Breast Cancer Resistance Protein. ChemMedChem 2012, 7 (7) , 1177-1180.
    94. Wesley Hsu, Ahmed Mohyeldin, Sagar R. Shah, Ziya L. Gokaslan, Alfredo Quinones-Hinojosa. Role of Cancer Stem Cells in Spine Tumors. Neurosurgery 2012, 71 (1) , 117-125.
    95. Anne Pick, Michael Wiese. Tyrosine Kinase Inhibitors Influence ABCG2 Expression in EGFR‐Positive MDCK BCRP Cells via the PI3K/Akt Signaling Pathway. ChemMedChem 2012, 7 (4) , 650-662.
    96. M Bauer, M Zeitlinger, R Karch, P Matzneller, J Stanek, W Jäger, M Böhmdorfer, W Wadsak, M Mitterhauser, J P Bankstahl, W Löscher, M Koepp, C Kuntner, M Müller, Oliver Langer. Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Blood–Brain Barrier: A Comparison With Rat Data. Clinical Pharmacology & Therapeutics 2012, 91 (2) , 227-233.
    97. Virginia Lanzotti, Orazio Taglialatela-Scafati, Ernesto Fattorusso, Attilio Di Pietro. Plant Compounds and Derivatives as Inhibitors of Cancer Cell Multidrug Resistance. 2011, 409-450.
    98. Cristian Ochoa Puentes, Peter Höcherl, Matthias Kühnle, Stefanie Bauer, Kira Bürger, Günther Bernhardt, Armin Buschauer, Burkhard König. Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2). Bioorganic & Medicinal Chemistry Letters 2011, 21 (12) , 3654-3657.
    99. Hong May Sim, Ker Yun Loh, Wee Kiang Yeo, Chong Yew Lee, Mei Lin Go. Aurones as Modulators of ABCG2 and ABCB1: Synthesis and Structure–Activity Relationships. ChemMedChem 2011, 6 (4) , 713-724.
    100. I. Leitner, J. Nemeth, T. Feurstein, A. Abrahim, P. Matzneller, H. Lagler, T. Erker, O. Langer, M. Zeitlinger. The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. Journal of Antimicrobial Chemotherapy 2011, 66 (4) , 834-839.
    Load all citations

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect